Who We Are
We are a highly specialized venture capital firm dedicated to unlocking value in the critical, often undervalued, sector of pre-regulatory approved diagnostic platforms. We exclusively target opportunities where the core technical development risk has been substantially mitigated, but where the perceived regulatory hurdle remains high. We see this intersection as the optimal point for strategic investment, enabling us to partner with companies that possess high-growth potential and a clear path to market.
Our investment thesis is powered by a unique blend of deep clinical rigor and disciplined business acumen. We do not just provide capital; we take an active operational role within our portfolio companies, leveraging our expertise—developed through decades of experience in clinical practice, advanced scientific research, and financial management—to serve as an extension of the management team. This hands-on approach allows us to directly de-risk complex regulatory pathways, accelerate product validation, and transition novel science into commercially successful, life-changing platforms.
Lennie Ryer CPA, CA
Chief financial officer
Lennie has occupied numerous CFO and board roles in both Public and Private entities and transitioned a number of companies from private to public in both the Canadian and US capital markets. In his 25+ years in the life science sector, Lennie has helped raised in excess of $750 million in equity-based transactions as well as negotiating credit facilities exceeding $225 million. His past experiences include CFO and VP Finance at ConjuChem Biotechnologies Inc. and CFO and VP Finance at Paladin Labs Inc. Prior to that, Lennie was Managing Partner of the Montreal office of BDO, where he specialized in mergers and acquisitions and taxation during his eighteen years in public practice.
Jordan Isenberg, MD-MBA, MSc
Founder
Dr. Jordan Isenberg, Founder of Isenberg Ventures, operates at the intersection of medicine, technology, and policy. He brings a rare, three-dimensional perspective—clinical, operational, and strategic to the diligence and growth of early-stage global healthcare ventures. Committed to obtaining superior risk-weighted financial returns with outsized system-level impact, his investment thesis is sharply focused on transformative opportunities in diagnostic platforms, physical diagnostic infrastructure, and clinically validatable software.
He holds an MDCM/MBA (Doctor of Medicine, Master of Surgery, Master of Business Administration) complemented by postgraduate medical training in both Ophthalmology and Pathology. This dual competency provides a critical edge in evaluating medical market needs and technological feasibility.
Beyond his clinical and business credentials, Dr. Isenberg possesses significant high-level policy and governance expertise. He served as a Public Policy and Leadership Fellow with Action Canada and advised the Québec Ministry of Finance on healthcare strategy. His capacity for large-scale economic strategy is underscored by his role as a Technical Advisor to Guatemala at the United Nations, where he played a key role in raising $3.5B for a carbon finance initiative.
A dedicated innovator and subject matter expert, Dr. Isenberg has significantly contributed to academic literature, authoring 16 peer-reviewed publications and presenting 21 conference abstracts on topics spanning clinical research, health economics, and finance.